STAT3 and apoptosis regulators: Bak and Bcl-xL in endometrioid adenocarcinomas of different estrogen receptor-α immunoprofile

Gynecological Endocrinology

Volumn 27, Issue 8, 2011, Pages 536-540

  Wincewicz, Andrzej ^a   Baltaziak, Marek ^a,b   Kanczuga Koda, Luiza ^a   Koda, Mariusz ^a,b   Sulkowska, Urszula ^b   Famulski, Waldemar ^a   Sulkowsk, Stanislaw ^a,b  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b Jedrzej Sniadecki Memorial Hospital   (Poland)

Author keywords

Apoptosis regulators; ER alpha; STAT3

Indexed keywords

APOPTOSIS REGULATORY PROTEIN; ESTROGEN RECEPTOR ALPHA; PEROXIDASE; PROTEIN BAK; PROTEIN BCL XL; STAT3 PROTEIN; UVOMORULIN;

ADULT; ARTICLE; CANCER CELL; CANCER CLASSIFICATION; CANCER GRADING; CANCER STAGING; CYTOPLASM; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; ENZYME ACTIVITY; FEMALE; HORMONE RESPONSE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION;

AGE FACTORS; AGED; APOPTOSIS REGULATORY PROTEINS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-X PROTEIN; CARCINOMA, ENDOMETRIOID; CELL NUCLEUS; CYTOPLASM; ENDOMETRIAL NEOPLASMS; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASM STAGING; RECEPTORS, PROGESTERONE; STAT3 TRANSCRIPTION FACTOR;

EID: 79959952669     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2010.507286     Document Type: Article

References (20)

1. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10-17. (Pubitemid 13194678)
2. Samarnthai N, Hall K, Yeh IT. Molecular profiling of endometrial malignancies. Obstet Gynecol Int 2010;2010: 162363.
3. Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol 2000;13:295-308. (Pubitemid 30207514)
4. Catalano S, Giordano C, Rizza P,GuG, Barone I, Bonofiglio D, Giordano F, Malivindi R, Gaccione D, Lanzino M, De Amicis F, Andò S. Evidence that leptin through STAT and CREB signaling enhances cyclin D1 expression and promotes human endometrial cancer proliferation. J Cell Physiol 2009;218:490-500.
5. Chen CL, Hsieh FC, Lieblein JC, Brown J, Chan C, Wallace JA, Cheng G, Hall BM, Lin J. Stat3 activation in human endometrial and cervical cancers. Br J Cancer 2007;96:591-599.
6. Pallares J, Mart́nez-Guitarte JL, Dolcet X, Llobet D, Rue M, Palacios J, Prat J, Matias-Guiu X. Survivin expression in endometrial carcinoma: a tissue microarray study with correlation with PTEN and STAT-3. Int J Gynecol Pathol 2005;24:247-253. (Pubitemid 40885078)
7. Binai NA, Damert A, Carra G, Steckelbroeck S, Löwer J, Löwer R, Wessler S. Expression of estrogen receptor alpha increases leptin-induced STAT3 activity in breast cancer cells. Int J Cancer 2010;127:55-66.
8. Yuan R, Kay A, Berg WJ, Lebwohl D. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol 2009;2:45.
9. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009;105: 103-104.
10. Wincewicz A, Koda M, Sulkowska M, Kanczuga-Koda L, Sulkowski S. Comparison of STAT3 with HIF-1a, Ob and ObR expressions in human endometrioid adenocarcinomas. Tissue Cell 2008;40:405-410.
11. Atkinson GP, Nozell SE, Benveniste ET. NF-kB and STAT3 signaling in glioma: targets for future therapies. Expert Rev Neurother 2010;10:575-586.
12. Yoon YK, Kim HP, Han SW, Oh do Y, Im SA, Bang YJ, Kim TY. KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach. Mol Carcinog 2010;49:353-362.
13. Ho JN, Kang GY, Lee SS, Kim J, Bae IH, Hwang SG, Um HD. Bcl-X(L) and STAT3 mediate malignant actions of g-irradiation in lung cancer cells. Cancer Sci 2010 Mar 4. [Epub ahead of print].
14. Huang S, Sinicrope FA. Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells. Mol Cancer Ther 2010;9:742-750.
15. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM (TARGET Study Group). Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-134. (Pubitemid 46089673)
16. Giglia JL, Antonia SJ, Berk LB, Bruno S, Dessureault S, Finkelstein SE. Systemic therapy for advanced hepatocellular carcinoma: past, present, and future. Cancer Control 2010;17: 120-129.
17. Zagouri F, Bozas G, Kafantari E, Tsiatas M, Nikitas N, Dimopoulos MA, Papadimitriou CA. Endometrial cancer: what is new in adjuvant and molecularly targeted therapy? Obstet Gynecol Int 2010;2010:749579.
18. Llobet D, Eritja N, Yeramian A, Pallares J, Sorolla A, Domingo M, Santacana M, Gonzalez-Tallada FJ, Matias- Guiu X, Dolcet X. The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms. Eur J Cancer 2010;46:836-850.
19. Trovato M, Grosso M, Vitarelli E, Ruggeri RM, Alesci S, Trimarchi F, Barresi G, Benvenga S. Distinctive expression of STAT3 in papillary thyroid carcinomas and a subset of follicular adenomas. Histol Histopathol 2003;18:393-399. (Pubitemid 36362056)
20. Trovato M, D'Armiento M, Lavra L, Ulivieri A, Dominici R, Vitarelli E, Grosso M, Vecchione R, Barresi G, Sciacchitano S. Expression of p53/HGF/c-met/STAT3 signal in fetuses with neural tube defects. Virchows Arch 2007;450:203-210. (Pubitemid 46295238)